MedTrace Logo

Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic BMT for Severe SCD

NCT00228631 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2014-05-26

No results posted yet for this study

Summary

In this study, patient blood samples from NMA transplants will be provided by Pittsburgh, and samples from myeloablative transplants will be provided by Atlanta (comparative controls). Samples would be obtained pre- and post-BMT from the recipient at a total of 7 timepoints, and from the donor at one timepoint.

Conditions

Sponsors & Collaborators

  • Emory University

    lead OTHER

Principal Investigators

  • Ann Haight, MD · Children's Healthcare of Atlanta/Emory

Eligibility

Min Age
6 Months
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2011-08-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00228631 on ClinicalTrials.gov